Celldex Therapeutics to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2016
March 17 2016 - 4:01PM
Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the
Company and its collaborating investigators will present seven
posters with new clinical and preclinical data at the American
Association for Cancer Research (AACR) Annual Meeting 2016 in New
Orleans.
Highlights include immune response data from the ongoing Phase
1/2 study of varlilumab and nivolumab in multiple solid tumors, the
role of gpNMB as a relevant therapeutic target across multiple
cancers and a late-breaking poster from the Phase 1
investigator-sponsored study of CDX-301 (Flt3L) in B-cell
lymphomas.
The following Celldex-sponsored abstracts have been selected for
poster presentations at AACR:
- Title: Phase 1 results from the combination of an
immune-activating anti-CD27 antibody (varlilumab) in combination
with PD-1 blockade (nivolumab): activation across multiple immune
pathways without untoward immune-related adverse events Date/Time:
Monday, April 18, 8:00 a.m. – 12:00 p.m. CDT Location: Section 13
Abstract: CT023
- Title: Glycoprotein NMB (gpNMB) overexpression is prevalent in
human cancers: pancreatic cancer, non-small cell lung cancer, head
and neck cancer, and osteosarcoma Date/Time: Wednesday, April 20,
8:00 a.m. – 12:00 p.m. CDT Location: Section 27 Abstract:
5032
- Title: IHC and RT-PCR assays for detection of cancer antigen
NY-ESO-1 in human tissues Date/Time: Monday, April 18, 8:00 a.m. –
12:00 p.m. CDT Location: Section 21 Abstract: 1373
- Title: Development and characterization of novel CD40 antibody
agonists for cancer immunotherapy Date/Time: Wednesday, April 20,
8:00 a.m. – 12:00 p.m. CDT Location: Section 22 Abstract: 4866
The
following investigator-sponsored abstracts have been selected for
poster presentations at AACR:
- Title: In situ vaccination of low-grade lymphoma with
intratumoral Flt3L and poly-ICLC with low-dose
radiotherapyDate/Time: Monday, April 18, 8:00 a.m. – 12:00 p.m.
CDTLocation: Section 10Abstract: LB-081
- Title: Targeting GPNMB with 89Zr-CR011 for PET imaging of
triple negative breast cancer Date/Time: Tuesday, April 19, 1:00
p.m. – 5:00 p.m. CDT Location: Section 33 Abstract: 4209
- Title: Targeting the melanosome: overcoming MAPK-inhibitor
resistance in melanomaDate/Time: Sunday, April 17, 1:00 p.m. – 5:00
p.m. CDTLocation: Section 16Abstract: 296
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address
devastating diseases for which available treatments are inadequate.
Our pipeline is built from a proprietary portfolio of antibodies
and immunomodulators used alone and in strategic combinations to
create novel, disease-specific therapies that induce, enhance or
suppress the body's immune response. Visit www.celldex.com.
Contact:
Sarah Cavanaugh
Vice President of Investor Relations & Corp Communications
Celldex Therapeutics, Inc.
(781) 433-3161
scavanaugh@celldex.com
Charles Liles
Manager of Investor Relations & Corp Communications
Celldex Therapeutics, Inc.
(781) 433-3107
cliles@celldex.com
Media Contact:
Dan Budwick
Pure Communications, Inc.
(973) 271-6085
dan@purecommunicationsinc.com
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Sep 2023 to Sep 2024